Long-term Study Of Paroxetine in Women and Men
NCT00264654 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2013-04-15
Summary
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD)
Conditions
- Social Phobia
Interventions
- DRUG
-
BRL29060A
- DRUG
-
paroxetine hydrochloride hydrate
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-10-31
- Primary Completion
- 2005-11-30
- Completion
- 2005-11-30
Countries
- Japan
Study Locations
More Related Trials
-
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
NCT00658372 ·Status: TERMINATED ·Phase: PHASE3
-
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
NCT00658762 ·Status: TERMINATED ·Phase: PHASE3
-
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
NCT00658008 ·Status: TERMINATED ·Phase: PHASE3
-
A Combination Therapy In Patients With Social Anxiety Disorder
NCT00403962 ·Status: COMPLETED ·Phase: PHASE2
-
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
NCT00266747 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
NCT00273039 ·Status: COMPLETED ·Phase: PHASE2
-
Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)
NCT00560612 ·Status: COMPLETED ·Phase: PHASE4
-
Concentration-QT Study of Paroxetine in Healthy Adults
NCT06065735 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of NTX-1472 in Social Anxiety Disorder
NCT07323784 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment Of Patients With Social Anxiety Disorder
NCT00397722 ·Status: COMPLETED ·Phase: PHASE2
-
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
NCT00332891 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
NCT00677352 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
NCT00191022 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
NCT05030350 ·Status: TERMINATED ·Phase: PHASE3
-
Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder
NCT00836069 ·Status: TERMINATED ·Phase: PHASE3
-
A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder
NCT00470483 ·Status: COMPLETED ·Phase: PHASE1
-
6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
NCT00738738 ·Status: WITHDRAWN ·Phase: PHASE3
-
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
NCT00735267 ·Status: TERMINATED ·Phase: PHASE3
-
Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
NCT00074802 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine
NCT02852577 ·Status: COMPLETED ·Phase: PHASE4
-
Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder
NCT00540098 ·Status: COMPLETED ·Phase: PHASE4
-
Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
NCT02622958 ·Status: COMPLETED ·Phase: PHASE3
-
Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)
NCT01371474 ·Status: COMPLETED
-
A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
NCT00542685 ·Status: COMPLETED ·Phase: PHASE3
-
Phased Treatment for Social Anxiety Disorder and Coping Behaviors in a Medical Setting
NCT00862212 ·Status: COMPLETED ·Phase: NA